Inuxair (Beclometasone Dipropionate, Formoterol Fumarate Dihydrate)

Beclometasone dipropionate is a synthetic glucocorticoid that binds to intracellular glucocorticoid receptors in airway cells. This interaction modulates gene transcription, suppressing the production of inflammatory cytokines, chemokines and adhesion molecules, thereby reducing airway inflammation and hyper‑responsiveness.

Formoterol is a selective long‑acting β2‑adrenergic receptor agonist. Activation of β2 receptors on bronchial smooth muscle increases intracellular cyclic AMP, leading to relaxation of the airway smooth muscle and bronchodilation that lasts for up to 12 hours, providing symptom relief.

The prescribed dose of Inuxair is individualized by the treating physician based on disease severity, patient age, and response to therapy. The prescriber determines the number of inhalations per day and may adjust the regimen during follow‑up visits; patients should follow the specific instructions on the prescription label.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Inuxair combines an inhaled corticosteroid with a long‑acting β2‑agonist in a single device, offering both anti‑inflammatory and bronchodilator effects. Compared with single‑component inhalers, it reduces the need for multiple devices and can improve adherence, while providing comparable efficacy to other combination products such as budesonide/formoterol or fluticasone/salmeterol.

Inuxair should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and heat. Do not expose the inhaler to extreme temperatures or direct sunlight, and keep the mouthpiece clean to maintain proper dosing performance.

Inuxair is delivered via a pressurised metered‑dose inhaler. The patient should shake the inhaler, exhale fully, place the mouthpiece between the lips, and press the canister while inhaling slowly and deeply. After each dose, hold the breath for about 10 seconds, then exhale gently. Rinsing the mouth after use helps reduce oral side effects.

Serious adverse events, although rare, can include paradoxical bronchospasm, severe allergic reactions such as anaphylaxis, adrenal suppression from prolonged corticosteroid exposure, and cardiovascular effects like tachycardia or arrhythmias due to the β2‑agonist component. Patients should seek immediate medical attention if they experience sudden worsening of breathing, swelling, or chest pain.

Inuxair is contraindicated in individuals with known hypersensitivity to beclometasone dipropionate, formoterol fumarate, or any excipients in the inhaler. It should also be avoided in patients who have experienced severe asthma attacks requiring oral corticosteroids, or in those with certain cardiac conditions where β2‑agonists may be unsafe, unless a physician determines that benefits outweigh risks.